Nomlabofusp + Placebo
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Dec 6, 2024 → Apr 28, 2025
NCT ID
NCT06681766About Nomlabofusp + Placebo
Nomlabofusp + Placebo is a phase 1 stage product being developed by Larimar Therapeutics for Friedreich Ataxia. The current trial status is terminated. This product is registered under clinical trial identifier NCT06681766. Target conditions include Friedreich Ataxia.
What happened to similar drugs?
0 of 9 similar drugs in Friedreich Ataxia were approved
Approved (0) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
6
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06681766 | Phase 1 | Terminated |
Competing Products
20 competing products in Friedreich Ataxia